Tuesday, March 24, 2015 | 11:45 AM - 4:00 PM
Speakers: P. Jeffrey Conn (Vanderbilt University), Ron Dror (Stanford University), Christopher Fotsch (Amgen), Corey Hopkins (Vanderbilt University), Whitney Nolte (Pfizer)
In this symposium, academic and industry scientists will describe the identification, characterization, and development of PAMs for challenging GPCRs.
Tuesday, April 7, 2015 | 8:30 AM - 4:30 PM
Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School, Boston, MA)
Speakers: Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle, MA), Jerome Ritz (Harvard Medical School), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology, Cambridge, MA)
Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.
Monday, April 27, 2015 | 8:30 AM - 4:15 PM
Speakers: Erwan Bezard (University of Bordeaux),
Patrick Brundin (Van Andel Institute), Anna Sauerbier (NPF Parkinson's International Centre of Excellence, Kings College London), Marie-Francoise Chesselet (David Geffen School of Medicine at UCLA), Maurizio Facheris (Michael J. Fox Foundation for Parkinson's Research), Horacio Kaufmann (NYU Langone Medical Center), Olivier Rascol (Toulouse University Hospital), Daniel Weintraub (University of Pennsylvania)
This symposium will review clinical tools for the diagnosis and treatment of non-motor symptoms of Parkinson's disease, discuss the disease mechanisms, and address preclinical models for the development of new therapeutics.
Tuesday, May 26, 2015 | 8:30 AM - 4:30 PM
Speakers: Richard Allen (Pfizer), John Burke (Applied BioMath), Nitin Mehrotra (US Food and Drug Administration), Tim Rolph (Pfizer), Vikram Sinha (US Food and Drug Administration), Peter Sorger (Harvard Medical School), Paul Watkins (Hamner-UNC Institute for Drug Safety Sciences)
Quantitative Systems Pharmacology (QSP) has been used successfully in drug discovery and development, yet lacks industry-wide adoption. This symposium highlights past successes and future challenges of using QSP in preclinical and clinical research.
Thursday, June 11, 2015 | 8:30 AM - 4:30 PM
Keynote Speaker: Jane Driver (Brigham and Women's Hospital)
Speakers: Kurt Brunden (University of Pennsylvania), Gary Landreth (ReXceptor), David M. Roy (Memorial Sloan Kettering Cancer Center), Li Huei Tsai (Massachusetts Institute of Technology), Raymond Scott Turner (Georgetown University), Hui Zheng (Baylor College of Medicine), Claes Wahlestedt (University of Miami, Miller School of Medicine), Carlos Buesa, PhD (Oryzon)
Does having cancer decrease your risk of developing neurodegenerative diseases? Why do many cancer drug targets overlap with targets for neurodegenerative diseases? This meeting will address these questions to help advance therapeutic development.
Wednesday, January 21, 2015 | 8:30 AM - 4:00 PM
Speakers: Jasna Brujic (New York University), Bridget Carragher, John Chodera, Oliver Clarke, Erik Debler, Nancy Greenbaum, David Hall, Barry Honig, Jinrang Kim (Columbia University), Nina Liu (Albert Einstein College of Medicine), Patrick Loria (Yale University), Sean McSweeney (Brookhaven National Lab), Clint Potter
The New York Area Structural Biology Discussion Group convenes twice annually and presents talks and poster sessions from graduate students, postdocs, and laboratory heads.
Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM
Speakers: Matthew D. Breyer (Eli Lilly and Company), Frank C. Brosius (University of Michigan Medical School), Benjamin D. Humphreys (Brigham and Women's Hospital), Matthias Meier (F. Hoffmann-La Roche Ltd), Shahnaz Shahinfar (S. Shahinfar Consulting, Inc. and The Children's Hospital of Philadelphia), Katalin Susztak (University of Pennsylvania), Aliza Thompson (Food and Drug Administration)
Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.
November 11 - 13, 2014
Keynote Speaker:Thomas R. Insel (National Institute of Mental Health)
Speakers: Tracy L. Bale (University of Pennsylvania), Jay Belsky (University of California, Davis), Maureen Black (University of Maryland), Pia Britto (UNICEF), Serena Counsell (King's College London), Martha Farah (University of Pennsylvania), Edward Frongillo (University of South Carolina), Michael Georgieff (University of Minnesota), Takao Hensch (Harvard University), Sharon Lynn Kagan (Columbia University), Patricia Kuhl (Washington University), Ed Lein (Allen Institute for Brain Science), Betsy Lozoff (University of Michigan), Linda Mayes (Yale School of Medicine), Andrew N. Meltzoff (Washington University), Charles A. Nelson (Harvard University and Boston Children's Hospital), Joseph Piven (UNC School of Medicine, CIDD), Dana Suskind (University of Chicago), Nim Tottenham (UCLA)
Discover the latest cognitive neuroscience research on infant and early childhood development; social, family, and nutritional factors that cause lasting changes to the brain; and intervention, education, and policy to help at-risk children.
Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM
Speaker: Michael S. Conte (University of California-San Francisco), Milan Fiala (David Geffen School of Medicine at UCLA), Gabrielle Fredman (Columbia University), Bruce Levy (Harvard University, Brigham and Women's Hospital), Dipak Panigrahy (Beth Israel Deaconess Medical Center, Harvard Medical School), Mauro Perretti (Queen Mary University of London), Charles N. Serhan (Brigham & Women's Hospital, Harvard Medical School), Patricia J. Sime (University of Rochester School of Medicine), Rudolph E. Tanzi (Massachusetts General Hospital)
Uncontrolled, chronic inflammation plays a key role in the progression of many diseases, and elucidation of biochemical pathways provides novel targets. This symposium reviews discoveries, approaches and opportunities for treatment and prevention.
Keynote Speaker: Thomas R. Insel (National Institute of Mental Health, NIH)
This eBriefing explores cognitive neuroscience research on early development, environmental factors that cause lasting changes in the brain, and initiatives to help at-risk children.
Edited by Mone Zaidi
(Mount Sinai School of Medicine, New York, New York)
A new series in Annals, MARROW presents cutting-edge manuscripts on basic, translational, and clinical bone and bone marrow biology and medicine.
Keynote Speaker: The Honorable Patrick J. Kennedy (Former U.S. Representative, Rhode Island; One Mind for Research; Kennedy Forum)
This eBriefing explores the translation of neuroscience breakthroughs into therapies for mental illness. A keynote lecture looks at strategies to dispel stigma surrounding mental illness so that new treatments are accessible to all.
Organizers: John A. Allen (Pfizer), Mercedes Beyna (Pfizer), Bryan L. Roth (University of North Carolina School of Medicine), and Jennifer Henry (formerly at The New York Academy of Sciences)
This eBriefing looks at how to exploit biased ligand signaling at GPCRs to improve therapeutics for cardiovascular and CNS disorders.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.